Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...
The FDA has approved Hympavzi to prevent bleeding episodes in hemophilia A and B patients aged 12 and older. This innovative ...
The U.S. Food and Drug Administration (FDA ... The approval is based on an open-label, multicenter study of 116 adult and pediatric male patients with either severe hemophilia A or severe ...
In a new study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs ...
The Food and Drug Administration (FDA) has approved Hympavzi (marstacimab-hncq ... and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without ...
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel hemophilia treatment ... a rival from Pfizer has gained an FDA nod.
Pfizer's Abrysvo is FDA-approved to prevent RSV in adults 18-59 ... before facing generic competition for their top-selling drugs. In 2023, an average of 440,000 people per week received RSV ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...